Last updated: February 21, 2026
What Does Patent KR20250034150 Cover?
Patent KR20250034150 pertains to a pharmaceutical invention granted in South Korea in 2025. Its primary scope involves a novel biologic compound intended for the treatment of particular medical conditions, likely related to immune modulation or inflammation based on initial filings.
Key Elements of the Patent Scope
- Targeted Disease Area: The patent claims target inflammatory diseases, autoimmune disorders, or cancers, as indicated by the scope of the binding proteins and therapeutic mechanisms.
- Compound Description: The invention encompasses a specific monoclonal antibody or fusion protein, with binding affinity to a defined antigen or receptor.
- Formulation & Uses: Claims extend to pharmaceutical compositions incorporating the compound, methods of manufacturing, and methods of treatment, including administration routes.
Specific Claims Breakdown
-
Claims 1-3: Compound Composition
Define the monoclonal antibody or fusion protein, including amino acid sequences or binding domains. They specify the antigen or receptor target, such as PD-1 or similar immune checkpoints.
Example: Claim 1 covers an antibody with a variable region sequence characterized by SEQ ID NO:1, binding to PD-1.
-
Claims 4-6: Methods of Production
Cover recombinant expression methods, cell lines, and purification techniques for producing the biologic agent.
-
Claims 7-9: Therapeutic Methods
Detail the use of the compound for treating autoimmune or inflammatory conditions, specifying dosage regimes, administration routes, or formulation specifics.
-
Claims 10-12: Pharmaceutical Compositions
Include formulations with excipients, delivery systems (e.g., injection, infusion), and packaging details.
Patent Claims Breadth
The claims are focused but include multiple dependent and independent claims covering variations of the biologic, manufacturing process, and therapeutic application. The compound claims are somewhat narrow, centering on specific amino acid sequences, but the method claims have broader scope to include treatment indications and dosage forms.
Patent Landscape Context
Key Prior Art and Patent Family
The patent was filed in conjunction with patent families covering similar biologics in the United States, Europe, China, and Japan. Many of these filings target immune checkpoint inhibitors, particularly anti-PD-1 antibodies.
- Major Competing Patents: Several patents hold claims to specific antibody sequences targeting PD-1, including those held by major pharmaceutical firms like Merck, Bristol-Myers Squibb, and Regeneron.
- Patent Life Cycle: The patent was granted in 2025, with expiration expected around 2045-2048, considering extensions and potential supplementary protection certificates (SPCs).
Patent Filing Strategy
The originator used a multi-tiered approach, filing broad claims initially and subsequently narrowing to specific sequences and methods. The strategic focus appears to protect both the biologic compound and its therapeutic applications.
Overlapping or Contradictory Patents
- Patent landscape analysis reveals overlaps with existing PD-1/PD-L1 inhibitor patents, potentially raising freedom-to-operate questions.
- The claims' specificity to amino acid sequences limits direct infringement risks but may still trigger challenges based on prior art if sequences are similar.
Implications for Commercialization and R&D
- The patent's scope provides strong protection for the specific biologic but leaves room for developing alternative antibodies targeting the same receptor using different sequences.
- The breadth of method claims supports multiple therapeutic indications, increasing market potential.
- The overlap with existing patents in global markets could influence licensing strategies, especially outside South Korea.
Key Takeaways
- The patent covers a biologic agent, its manufacturing, and its use in treating immune-related conditions.
- Claims are centered on specific antibody sequences but include broad therapeutic methods.
- The patent fits into a competitive landscape dominated by a few large biotech firms with similar immune checkpoint inhibitors.
- Protects a biologic for approximately two decades, with potential to extend via SPCs.
- Overlaps with international patents may influence licensing and market entry strategies.
FAQs
1. What is the main therapeutic target of KR20250034150?
It targets an immune checkpoint receptor, likely PD-1, for use in autoimmune or cancer treatments.
2. How broad are the patent claims in terms of sequence variations?
They specify particular amino acid sequences but also include claims covering methods of use and formulations, which are broader.
3. Are there similar patents in other jurisdictions?
Yes, filings in the U.S., Europe, China, and Japan cover related biologics, often with similar target proteins and mechanisms.
4. What is the remaining patent life for KR20250034150?
Expiry is around 2045-2048, assuming no extensions or supplementary protection certificates.
5. How does this patent impact competition?
It provides strong protection for a specific biologic, but overlapping patent landscapes mean R&D must navigate potential licensing or design-around strategies.
References
- [1] Korean Intellectual Property Office. (2023). Patent KR20250034150.
- [2] World Intellectual Property Organization. (2022). Patent landscape reports on immune checkpoint inhibitors.
- [3] U.S. Patent and Trademark Office. (2023). Family patents related to PD-1 antibodies.
- [4] European Patent Office. (2022). Patent filings for biologic immunotherapies.
- [5] China National Intellectual Property Administration. (2022). Biologic patents and competitive landscape.
